company background image
LAB

Standard BioTools NasdaqGS:LAB Stock Report

Last Price

US$1.23

Market Cap

US$96.7m

7D

-8.9%

1Y

-81.4%

Updated

25 Sep, 2022

Data

Company Financials
LAB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LAB Stock Overview

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide.

Standard BioTools Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Standard BioTools
Historical stock prices
Current Share PriceUS$1.23
52 Week HighUS$6.67
52 Week LowUS$1.15
Beta1.2
1 Month Change-12.14%
3 Month Change-31.67%
1 Year Change-81.36%
3 Year Change-73.89%
5 Year Change-75.60%
Change since IPO-91.23%

Recent News & Updates

Shareholder Returns

LABUS Life SciencesUS Market
7D-8.9%-5.0%-5.2%
1Y-81.4%-35.1%-23.0%

Return vs Industry: LAB underperformed the US Life Sciences industry which returned -35.1% over the past year.

Return vs Market: LAB underperformed the US Market which returned -23% over the past year.

Price Volatility

Is LAB's price volatile compared to industry and market?
LAB volatility
LAB Average Weekly Movement12.0%
Life Sciences Industry Average Movement9.7%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: LAB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: LAB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999615Michael Egholmhttps://www.fluidigm.com

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Standard BioTools Inc. Fundamentals Summary

How do Standard BioTools's earnings and revenue compare to its market cap?
LAB fundamental statistics
Market CapUS$96.75m
Earnings (TTM)-US$163.10m
Revenue (TTM)US$112.05m

0.9x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LAB income statement (TTM)
RevenueUS$112.05m
Cost of RevenueUS$97.17m
Gross ProfitUS$14.88m
Other ExpensesUS$177.98m
Earnings-US$163.10m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.07
Gross Margin13.28%
Net Profit Margin-145.56%
Debt/Equity Ratio23.6%

How did LAB perform over the long term?

See historical performance and comparison